INTRODUCTION: Carboxylesterase 1 (CES1) is the primary enzyme responsible for converting clopidogrel into biologically inactive carboxylic acid metabolites. METHODS: We genotyped a functional variant in CES1, G143E, in participants of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study (n=566) and in 350 patients with coronary heart disease treated with clopidogrel, and carried out an association analysis of bioactive metabolite levels, on-clopidogrel ADP-stimulated platelet aggregation, and cardiovascular outcomes. RESULTS: The levels of clopidogrel active metabolite were significantly greater in CES1 143E-allele carriers (P=0.001). Consistent with these findings, individuals who carried the CES1 143E-allele showed a better clopidogrel response as measured by ADP-stimulated platelet aggregation in both participants of the PAPI study (P=0.003) and clopidogrel-treated coronary heart disease patients (P=0.03). No association was found between this single nucleotide polymorphism and baseline measures of platelet aggregation in either cohort. CONCLUSION: Taken together, these findings suggest, for the first time, that genetic variation in CES1 may be an important determinant of the efficacy of clopidogrel.
INTRODUCTION:Carboxylesterase 1 (CES1) is the primary enzyme responsible for converting clopidogrel into biologically inactive carboxylic acid metabolites. METHODS: We genotyped a functional variant in CES1, G143E, in participants of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study (n=566) and in 350 patients with coronary heart disease treated with clopidogrel, and carried out an association analysis of bioactive metabolite levels, on-clopidogrel ADP-stimulated platelet aggregation, and cardiovascular outcomes. RESULTS: The levels of clopidogrel active metabolite were significantly greater in CES1 143E-allele carriers (P=0.001). Consistent with these findings, individuals who carried the CES1 143E-allele showed a better clopidogrel response as measured by ADP-stimulated platelet aggregation in both participants of the PAPI study (P=0.003) and clopidogrel-treated coronary heart diseasepatients (P=0.03). No association was found between this single nucleotide polymorphism and baseline measures of platelet aggregation in either cohort. CONCLUSION: Taken together, these findings suggest, for the first time, that genetic variation in CES1 may be an important determinant of the efficacy of clopidogrel.
Authors: P Savi; J M Pereillo; M F Uzabiaga; J Combalbert; C Picard; J P Maffrand; M Pascal; J M Herbert Journal: Thromb Haemost Date: 2000-11 Impact factor: 5.249
Authors: Cody J Peer; Shawn D Spencer; Dustin A H VanDenBerg; Michael A Pacanowski; Richard B Horenstein; William D Figg Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2011-11-26 Impact factor: 3.205
Authors: J P Lewis; A S Fisch; K Ryan; J R O'Connell; Q Gibson; B D Mitchell; H Shen; K Tanner; R B Horenstein; R Pakzy; U S Tantry; K P Bliden; P A Gurbel; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2011-08-31 Impact factor: 6.875
Authors: S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2011-06-29 Impact factor: 6.875
Authors: J P Lewis; S H Stephens; R B Horenstein; J R O'Connell; K Ryan; C J Peer; W D Figg; S D Spencer; M A Pacanowski; B D Mitchell; A R Shuldiner Journal: J Thromb Haemost Date: 2013-09 Impact factor: 5.824
Authors: E Katriina Tarkiainen; Aleksi Tornio; Mikko T Holmberg; Terhi Launiainen; Pertti J Neuvonen; Janne T Backman; Mikko Niemi Journal: Br J Clin Pharmacol Date: 2015-06-11 Impact factor: 4.335